摘要
Background:Whether pembrolizumab given both before surgery(neoadjuvant therapy)and after surgery(adjuvant therapy),as compared with pembrolizumab given as adjuvant therapy alone,would increase event-free survival among patients with resectable stage Ⅲ or Ⅳ melanoma is unknown.
出处
《四川生理科学杂志》
2023年第3期467-467,共1页
Sichuan Journal of Physiological Sciences
